300122.SZ
智飞生物
SZSE · Healthcare · C 制造业 · CN
CNY 12.83
−7.70%Year over year
Reported trailing growth
- Revenue
- -48.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +680.1%
- Operating cash flow
- +1242.7%
Forward estimates
Based on analyst estimates
- Revenue
- -6.3%
- EBITDA
- +104.0%
- EPS
- +98.5%
Three-year CAGR
- Revenue
- -38.4%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +104.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026